BSPED2013
13 November 2013
09:30-18:30
Registration
16:45-18:15
Industry Sponsored Satellite Symposium - Updates on Turner Syndrome and Prader-Willi Syndrome
Chair(s): M Donaldson (Glasgow) & E Gevers (London)
Supported by Pfizer Limited
16:45
Turner syndrome: what can we do better?
17:30
Prader-Willi Syndrome: update on MDT management of children with Prader-Wili Syndrome
18:15-19:00
Welcome Reception
14 November 2013
08:00-18:00
Registration
08:30-09:00
Welcome and Lighting of the Lamp
J Cohen (Brighton)
09:00-10:30
Oral Communications 1
Chair(s): D Ismail (Brighton) & J Barton (Bristol)
09:00
OC1.1
Growth Hormone (GH) testing – Reducing the need for a second test for the diagnosis of Growth Hormone deficiency
09:10
OC1.2
A single centre audit of the 2012 UK Newborn Screening Programme Guidelines for pre-term infants
09:20
OC1.3
The Utility Of AMH For Predicting Testosterone Response To HCG Stimulation In Children With Suspected DSD
09:30
OC1.4
Abnormal glucose homeostasis in survivors of Childhood Acute Lymphoblastic Leukaemia (ALL) treated with Bone Marrow Transplantation (BMT) and Total Body Irradiation (TBI) is associated with reduced Beta-cell reserve and pancreatic volume
09:40
OC1.5
Novel Genes Affecting the Timing of Puberty
09:50
OC1.6
Oral bisphosphonates as prophylaxis of steroid-induced osteoporosis in Duchenne Muscular Dystrophy
10:00
OC1.7
A mutation in thioredoxin reductase 2 (TXNRD2) is associated with familial glucocorticoid deficiency (FGD)
10:10
OC1.8
The repressor activity of the Wnt/β-Catenin effector Tcf3/TCF7L1 is required for normal hypothalamic-pituitary development
10:20
OC1.9
Genetic characterisation of short children with potential defects of GH action by single gene sequencing
10:30-11:00
Tea & Coffee
11:00-12:30
Symposium 1 – care and controversies: present and future
Chair(s): H Spoudeas (London) & H Gleeson (Leicester)
11:00
S1.1
Gonadal Function and Fertility after Cancer Treatment in Childhood
11:30
S1.2
Preservation of fertility
12:00
S1.3
SAGhe: GH safety and long term concerns
12:30-14:00
Lunch
13:15-14:00
Poster Tour
14:00-15:00
Oral Communications 2
Chair(s): S Kanumakala (Brighton) & N Davis (Southampton)
14:00
OC2.1
Whole Exome Sequencing as a diagnostic tool in adrenal insufficiency
14:06
OC2.2
Increased bone area without reduction in volumetric bone mineral density in children treated with glucocorticoids for nephrotic syndrome
14:12
OC2.3
Clinical phenotype of patients with MCM4 mutation suggests pubertal delay in males
14:18
OC2.4
FGF21 causes GH resistance in human chondrocytes through activation of SOCS2 and inhibition of IGF1 expression
14:24
OC2.5
Continuous Subcutaneous Infusion of Parathyroid Hormone reduces PTH requirement in patient with activating mutation of the calcium sensing receptor
14:30
OC2.6
Review of the clinical scoring systems in Silver-Russell syndrome and development of modified diagnostic criteria to guide molecular genetic testing
14:36
OC2.7
Novel lethal form of hypopituitarism associated with the first recessive LHX4 mutation
14:42
OC2.8
Establishing a national audit of paediatric GH prescribing
14:48
OC2.9
A comprehensive next generation sequencing-based strategy for genetic diagnosis in congenital hypothyroidism (CH)
14:54
OC2.10
A new approach to the definition and diagnosis of adrenal insufficiency during inhaled corticosteroid therapy for asthma
15:00-15:30
Tea & Coffee
15:30-16:30
Symposium 2 - Recent advances in CAH management
Chair(s): N Krone (Birmingham) & F Ahmed (Glasgow)
15:30
S2.1
CaHASE – A UK collaborative study on CAH in adults
16:00
S2.2
Paediatric surveillance for CAH – informing newborn screening policy
16:45-18:00
BSPED Annual General Meeting
19:00-19:30
Pre-Dinner Welcome Reception
19:30-23:59
Conference Dinner
15 November 2013
08:00-15:30
Registration
08:00-08:50
Industry Sponsored Satellite Symposium - Optimising endocrine care in the Hypopituitary Patient
Chair(s): M Dattani (London)
Supported by Sandoz Biopharmaceuticals
08:00
Welcome and introductions
08:05
Thyroxine and Hydrocortisone Replacement
08:25
Growing up with Growth Hormone Deficiency – indicators and measures of successful endocrine care
08:45
Questions to the panel
09:00-10:30
Symposium 3 - Present and future: novelty and goals
Chair(s): R Williams (Cambridge) & C Agwu (Birmingham)
09:00
S3.1
Benefits of diabetes networks and beyond
09:30
S3.2
Complications of Type 1 Diabetes - Current dilemmas
10:00
S3.3
What are the barriers of implementation to BPT
10:30-11:00
Tea & Coffee
11:00-11:30
BSPED 2011 Research Award Winners Presentation
Chair(s): R Amin (London)
11:00
Does SOX2 regulate bone stem / progenitor cells?
11:10
Understanding the role of Vitamin D in skeletal muscle function using
11:20
Interplay of the fetal adrenal cortex, placental corticotrophin-releasing hormone
11:30-12:30
Oral Communications 3
Chair(s): R Kapoor (London) & J Greening (Leicester)
11:30
OC3.1
Catch up growth and insulin sensitivity in adolescent children born preterm
11:40
OC3.2
GAD and IA2 autoantibody positivity is associated with a requirement for insulin treatment: results of the UK national paediatric Type 2 Diabetes cohort
11:50
OC3.3
Successful Treatment of Four Patients with Severe Hyperinsulinaemic Hypoglycaemia with a novel therapy using mTOR Inhibitor
12:00
OC3.4
Successful Use of Long Acting Octreotide in Treatment of Congenital Hyperinsulinism
12:10
OC3.5
Loss of the tumour suppressor micro-RNA 34a, and anti tumour cellular immunity in paediatric obesity – is obesity increasing the future risk of cancer in children?
12:20
OC3.6
A feasibility study of intra-gastric balloons (supported by a lifestyle programme) for the treatment of severe adolescent obesity - the (BOB) Study
12:30-13:06
Oral Communications 4
Chair(s): R Kapoor (London) & J Greening (Leicester)
12:30
OC4.1
Risk factors for emergency hospital admission for diabetic ketoacidosis in children and young people: national cross-sectional analysis
12:36
OC4.2
Maturity-onset diabetes of Young 5 (MODY5) with Gallbladder duplication cyst: a novel case
12:42
OC4.3
The Incentive Trial: Do financial rewards improve glycaemic control in teenagers with poorly controlled Type 1 Diabetes?
12:48
OC4.4
Special Features of Neonatal Diabetes in a Series of Arab Patients from the Gulf Region
12:54
OC4.5
Peer Review: A tool to improve Paediatric Diabetes services
13:00
OC4.6
Increased urinary Megalin and Cubulin excretion in children with Type 1 Diabetes Mellitus (T1DM) - an association with low molecular weight protein loss
13:06-14:00
Lunch
14:00-14:45
Plenary Guest Lecture
Chair(s): P Hindmarsh (London)
14:00 -14:45
PL1
Early intervention on type 1 diabetes
14:45-15:45
Symposium 4 - Debate: Pump Vs MDI in all children with T1DM
Chair(s): T Cheetham (Newcastle) & J Blair (Liverpool)
14:45
S4.1
Pump therapy in all newly diagnosed T1DM
15:15
S4.2
MDI in all newly diagnosed T1DM
15:45-16:00
Close of meeting